Allon Therapeutics has announced that patient enrollment has begun for a Phase II human clinical trial evaluating the company's product AL-208 as a treatment for the mild cognitive impairment (MCI) that commonly occurs following coronary artery bypass graft (CABG) surgery.

The initial portion of the study in which all patients receive AL-208 will be open-label to confirm safety, followed by a randomized placebo-controlled portion. In total, approximately 200 patients will be treated with AL-208 (or placebo) during surgery. The patients will be assessed using standard cognitive tests, administered several weeks after surgery, to determine the impact on cognitive function of patients treated with AL-208 versus patients in the control group. The trial will be conducted in approximately 20 hospitals in the U.S. and Canada.